Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Petrie

Showing results (511-520 of 557) with videos related to

Pageof 56
Sort By:
JAMA Cardiology|September 1, 2018
One-Year Safety and Clinical Outcomes of a Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction in the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (REDUCE LAP-HF I) Trial: A Randomized Clinical TrialSanjiv J Shah, Ted Feldman, Mark J Ricciardi, et al.
European Heart Journal|August 26, 2020
Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registryKaren Sliwa, Mark C Petrie, Peter van der Meer, et al.
European Journal of Heart Failure|December 10, 2019
European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failurePetar M Seferović, Andrew J S Coats, Piotr Ponikowski, et al.
European Journal of Heart Failure|November 4, 2025
Finerenone in patients with severe heart failure: The FINEARTS-HF trialRiccardo M Inciardi, Henri Lu, Brian L Claggett, et al.
European Journal of Heart Failure|December 15, 2024
Empagliflozin to prevent worsening of left ventricular volumes and systolic function after myocardial infarction (EMPRESS-MI)Jaclyn Carberry, Mark C Petrie, Matthew M Y Lee, et al.
European Heart Journal|March 30, 2020
Effects of dapagliflozin in DAPA-HF according to background heart failure therapyKieran F Docherty, Pardeep S Jhund, Silvio E Inzucchi, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|February 16, 2026
A Bayesian analysis of finerenone in heart failure with mildly reduced and preserved ejection fraction: a pre-specified analysis of FINEARTS-HFAlasdair D Henderson, Kieran F Docherty, Atefeh Talebi, et al.
Circulation. Heart Failure|January 29, 2026
Finerenone, Liver Biomarkers, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: An Analysis of FINEARTS-HFJawad H Butt, Alasdair D Henderson, Pardeep S Jhund, et al.
Trials|April 15, 2022
Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS)Seonaidh Cotton, Graham Devereux, Hassan Abbas, et al.
European Heart Journal|May 21, 2023
Dapagliflozin vs. metolazone in heart failure resistant to loop diureticsSu Ern Yeoh, Joanna Osmanska, Mark C Petrie, et al.
Pageof 56

Showing results (511-520 of 557) with videos related to

Sort By:
Pageof 56
JAMA Cardiology|September 1, 2018
One-Year Safety and Clinical Outcomes of a Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction in the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (REDUCE LAP-HF I) Trial: A Randomized Clinical TrialSanjiv J Shah, Ted Feldman, Mark J Ricciardi, et al.
European Heart Journal|August 26, 2020
Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registryKaren Sliwa, Mark C Petrie, Peter van der Meer, et al.
European Journal of Heart Failure|December 10, 2019
European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failurePetar M Seferović, Andrew J S Coats, Piotr Ponikowski, et al.
European Journal of Heart Failure|November 4, 2025
Finerenone in patients with severe heart failure: The FINEARTS-HF trialRiccardo M Inciardi, Henri Lu, Brian L Claggett, et al.
European Journal of Heart Failure|December 15, 2024
Empagliflozin to prevent worsening of left ventricular volumes and systolic function after myocardial infarction (EMPRESS-MI)Jaclyn Carberry, Mark C Petrie, Matthew M Y Lee, et al.
European Heart Journal|March 30, 2020
Effects of dapagliflozin in DAPA-HF according to background heart failure therapyKieran F Docherty, Pardeep S Jhund, Silvio E Inzucchi, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|February 16, 2026
A Bayesian analysis of finerenone in heart failure with mildly reduced and preserved ejection fraction: a pre-specified analysis of FINEARTS-HFAlasdair D Henderson, Kieran F Docherty, Atefeh Talebi, et al.
Circulation. Heart Failure|January 29, 2026
Finerenone, Liver Biomarkers, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: An Analysis of FINEARTS-HFJawad H Butt, Alasdair D Henderson, Pardeep S Jhund, et al.
Trials|April 15, 2022
Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS)Seonaidh Cotton, Graham Devereux, Hassan Abbas, et al.
European Heart Journal|May 21, 2023
Dapagliflozin vs. metolazone in heart failure resistant to loop diureticsSu Ern Yeoh, Joanna Osmanska, Mark C Petrie, et al.
Pageof 56